Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) VP Ravindra Kumar unloaded 9,000 shares of the stock on the open market in a transaction dated Thursday, August 14th. The stock was sold at an average price of $29.97, for a total value of $269,730.00. Following the sale, the vice president now directly owns 31,890 shares in the company, valued at approximately $955,743. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Acceleron Pharma (NASDAQ:XLRN) traded down 0.50% on Friday, hitting $29.81. The stock had a trading volume of 140,234 shares. Acceleron Pharma has a 52 week low of $16.78 and a 52 week high of $57.89. The stock has a 50-day moving average of $29.77 and a 200-day moving average of $36.09. The company’s market cap is $947.9 million.

Acceleron Pharma (NASDAQ:XLRN) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.55) by $0.01. Analysts expect that Acceleron Pharma will post $-1.44 EPS for the current fiscal year.

XLRN has been the subject of a number of recent research reports. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday. They set an “outperform” rating and a $47.00 price target on the stock. Four equities research analysts have rated the stock with a buy rating, Acceleron Pharma currently has a consensus rating of “Buy” and a consensus target price of $51.00.

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.